The exploratory AKI data are directionally positive but non-prespecified — watch for any follow-on confirmatory trial announcements or partnership interest. The stock is highly volatile (market cap ~$63M) and may gap on the news, but the data are hypothesis-generating, not pivotal.
Price Chart
Executive Summary
Edesa Biotech reported favorable exploratory data for paridiprubart in acute kidney injury (AKI) patients with respiratory distress at the ERA Congress. The data showed a 32% relative reduction in 28-day mortality and a 23% relative reduction in MAKE30 composite endpoint vs placebo, with consistent safety. These are exploratory, non-prespecified analyses from a 101-patient AKI subgroup, not confirmatory — the stock may react positively but the data are hypothesis-generating only.
Key Facts
- Paridiprubart + SOC reduced adjusted 28-day mortality to 33% from 49% (32% relative reduction, nominal p<0.005) in AKI patients with respiratory distress.
- MAKE30 composite endpoint reduced to 41% from 53% (23% relative reduction, nominal p<0.005).
- Data are exploratory, post hoc, not prespecified — nominal p-values not adjusted for multiplicity.
- AKI cohort of 101 patients derived from Phase 2 and Phase 3 ARDS studies; ~90% had moderate-to-severe ARDS at baseline.
- Safety profile consistent with prior studies; no significant differences in adverse events vs placebo.
- Data presented at the 63rd European Renal Association Congress (oral presentation).
Financial Impact
No financial figures provided; early-stage biotech with no revenue. Positive exploratory data may support pipeline value and future trial design.
Risk Factors
- Exploratory, non-prespecified analyses — results may not replicate in confirmatory studies.
- No approved pharmacological therapies for AKI exist; regulatory path is uncertain.
- Company is pre-revenue with limited cash runway (not disclosed in this release).
- Nominal p-values not adjusted for multiplicity — false discovery risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307429 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $2.59 | awaiting T+20 | — | $2.63 (+1.54%) |
Oct 15, 2026 12d ago | 8-K | $2.67 | awaiting T+20 | — | $2.63 (−1.50%) |
Oct 15, 2026 12d ago | Press Release | $2.67 | awaiting T+20 | — | $2.63 (−1.50%) |
Aug 19, 2026 9w ago | Press Release | $4.76 $4.14 | ▲ +13.03% | ▲ +13.03% | $2.63 (+44.75%) |
Jul 14, 2026 15w ago | EFFECT | $6.74 $5.52 | ▲ +18.10% | ▲ +20.59% | $2.63 (+60.98%) |
Jul 2, 2026 16w ago | S-3 | $7.50 $5.25 | ▼ −30.00% | ▼ −29.59% | $2.63 (−64.93%) |
Jun 5, 2026 20w ago | 8-K | $5.46 $7.21 | ▲ +32.05% | ▲ +30.19% | $2.63 (−51.83%) |
Jun 5, 2026 20w ago | Press Release | $5.46 $7.21 | ▲ +32.05% | ▲ +30.19% | $2.63 (−51.83%) |
May 29, 2026 21w ago | 8-K | $6.69 $8.13 | ▲ +21.52% | ▲ +22.82% | $2.63 (−60.69%) |
May 19, 2026 23w ago | Press Release | $11.95 $6.88 | ▼ −42.43% | ▼ −43.41% | $2.63 (−77.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers